Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Klose, H; Harbaum, L; Richter, MJ; Lichtblau, M; Marra, AM; Kabitz, HJ; Harutyunova, S; Milger-Kneidinger, K; Lange, TJ.
[Targeted therapy for pulmonary arterial hypertension in patients without comorbidities].
Pneumologie. 2023; 77(11):890-900
Doi: 10.1055/a-2145-4711
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Milger-Kneidinger Katrin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The 2022 guidelines on pulmonary hypertension from the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) provide therapeutic strategies that account for the variability in the clinical presentation of newly diagnosed patients. We summarize treatment recommendations for pulmonary arterial hypertension (PAH) in patients without significant comorbidities, particularly for idiopathic, hereditary, drug/toxin-induced, or connective tissue disease-associated PAH. In this group of patients, multidimensional assessments for short-term mortality risk guide initial treatment decisions and treatment decisions during follow-up. Upfront dual combination therapy (phosphodiesterase type-5 inhibitor and endothelin receptor antagonist) is recommended for low- and intermediate-risk patients, and triple therapy including a parenteral prostacyclin should be considered in high- or intermediate-high-risk patients. If a low or intermediate-low-risk profile cannot be achieved during therapy, sequential add-on therapy escalation with parenteral prostacyclin or a prostacyclin receptor agonist should be considered, and switching from a phosphodiesterase type-5 inhibitor to a guanylate cyclase stimulator may also be considered.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Pulmonary Arterial Hypertension - diagnosis, drug therapy
- Hypertension, Pulmonary - diagnosis, drug therapy
- Endothelin Receptor Antagonists - therapeutic use
- Prostaglandins I - therapeutic use
- Phosphoric Diester Hydrolases - therapeutic use
- Find related publications in this database (Keywords)
- pulmonary arterial hypertension
- calcium channel blockers
- endothelin receptor antagonists, Phosphodiesterase 5 inhibitors
- soluble guanylate cyclase stimulators
- prostazyklin analogues
- prostazyklin
- treatment strategies